Immunomodulatory effect of tigecycline on lipopolysaccharide-induced sepsis

ZHANG Lu,LI Xiang,FENG Meiqing,LEI Chen,JIANG Lijing,TONG Huan,TANG Weiyi
DOI: https://doi.org/10.16718/j.1009-7708.2023.02.003
2023-01-01
Abstract:Objective To investigate whether tigecycline can regulate the inflammatory response induced by lipopolysaccharide(LPS) in vivo and in vitro. Methods The effect of tigecycline on the proliferation activity of mouse mononuclear macrophages RAW264.7 was studied in vitro. The regulatory effect of tigecycline on the LPS-induced inflammatory response of RAW264.7 was investigated in vitro. Tigecycline was added to the cell suspension, followed by addition of LPS. The supernatants were collected at different time points in each test group. The level of cytokines was detected by ELISA. Low-dose LPS-induced inflammatory response was also studied in vivo. Mice were injected with tigecycline(6.5 mg/kg) via tail vein, followed by injection of LPS(15mg/kg) 2 hours later. Serum cytokines levels were detected by ELISA at each time point. The spleen was tested by flow cytometry after animal death. The mortality was recorded up to 24 hours. Results Tigecycline promoted the proliferation of macrophage RAW264.7. In vitro, tigecycline inhibited the inflammatory response of RAW264.7 cells induced by LPS and so reduced the release of IL-6, IFN-γ and CCL5 while increased the release of IL-10. Tigecycline also had a similar inhibitory effect on LPS-induced mice inflammatory response in vivo. Flow cytometry showed that tigecycline could promote M2 polarization of macrophages in endotoxemia. It has a protective effect on the death of mice. Conclusions Tigecycline has an immunomodulatory effect on LPSinduced inflammation, can inhibit the excessive immune reaction, and so has a protective effect on the host.
What problem does this paper attempt to address?